(UroToday.com) In the Proffered Paper session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on non-prostate cancer genitourinary tumors, Dr. Pfister presented results of the GETUG/AFU VESPER V05 phase III trial assessing dose dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin (dd-MVAC) compared to Gemcitabine and Cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy (NCT 01812369).